In Minnesota, lawmakers are currently reviewing the 340B prescription drug discount program, a federal system designed to help nonprofit hospitals access cheaper medicines for patients in need.
On paper, it’s meant to support vulnerable communities. But on the ground, the reality is more complex.
In rural “healthcare deserts,” leaders like Keith Harvey of Scenic Rivers Health say they face heavy administrative pressure while trying to stretch limited resources. At the same time, hospitals, pharmaceutical companies and policymakers are locked in debate over whether 340B is truly serving patients or creating new imbalances in the system.
Behind it all is a quiet but powerful clash involving hospitals, Pharma companies and lobbying groups shaping the future of healthcare access.
What do you think should programs like 340B be expanded, or reformed?
La rédaction
